Popular Trials
Procedure
LX9211 for Diabetic Neuropathy
Recruiting0 awardsPhase 2
Dallas, Texas
This trial is testing a new drug called LX9211 to see if it can reduce nerve pain in people with diabetes. The drug works by blocking pain signals in the nerves. Researchers want to find out if it is more effective than other treatments. A similar drug was previously tested for similar conditions but its development was halted due to safety concerns.
Virus Therapy
Rilematovir for Respiratory Syncytial Virus
Recruiting0 awardsPhase 2
Mesquite, Texas
The purpose of this study is to evaluate the efficacy of rilematovir compared to placebo with respect to the time to resolution of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) symptoms.
BOS-589 for Irritable Bowel Syndrome
Recruiting0 awardsPhase 2
Dallas, Texas
This study is being conducted to evaluate in participants with diarrhea-predominant Irritable Bowel Syndrome (IBS-D) the abdominal pain response to BOS-589 after 4 weeks of treatment and to evaluate the overall safety and tolerability of BOS-589 in the treatment of IBS-D during 4 weeks of treatment, relative to placebo (PBO).
Popular Filters
Phase 3 Trials
Janus Kinase (JAK) Inhibitor
Deucravacitinib for Lupus
Recruiting1 awardPhase 3
Colleyville, Texas
This trial is testing a new medication called deucravacitinib to see if it is safe and effective for people with moderate to severe lupus, a disease where the immune system attacks the body. The medication aims to reduce inflammation by targeting specific enzymes in the immune system.
Anticholinergic
Aclidinium Bromide for Chronic Obstructive Pulmonary Disease
Recruiting3 awardsPhase 3
Arlington, Texas
The purpose of this study is to evaluate the efficacy, safety and tolerability of aclidinium bromide doses compared with placebo in the treatment of moderate to severe, stable chronic obstructive pulmonary disease. The study will be 56 weeks in duration; a 2-week run-in period followed by a 12-week double-blind, placebo-controlled treatment period. This will be followed by an open-label 40-week treatment period and a 2-week follow up phone call. All patients will receive the higher Aclidinium Bromide during the 40-week open label treatment period.
Alkylating agents
Cyclophosphamide +2 More for Breast Cancer
Recruiting2 awardsPhase 3
Bessemer, Alabama
This trial is testing if adding the drug bevacizumab to standard chemotherapy can help prevent HER2-negative breast cancer from returning and improve survival rates. Researchers also want to learn about any side effects from the combination of drugs.
Corticosteroid
Dexamethasone +2 More for Multiple Myeloma
Recruiting4 awardsPhase 3
Dallas, Texas
The purpose of this study is to determine if Thalidomide + Dexamethasone or DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone is more effective in treating newly diagnosed patients with multiple myeloma. The number of patients whose multiple myeloma disappears for a period of time (complete Response) will be studied to make the determination of which treatment is more effective.
Trials With No Placebo
Alkylating agents
Cyclophosphamide +2 More for Breast Cancer
Recruiting2 awardsPhase 3
Bessemer, Alabama
This trial is testing if adding the drug bevacizumab to standard chemotherapy can help prevent HER2-negative breast cancer from returning and improve survival rates. Researchers also want to learn about any side effects from the combination of drugs.
Corticosteroid
Dexamethasone +2 More for Multiple Myeloma
Recruiting4 awardsPhase 3
Dallas, Texas
The purpose of this study is to determine if Thalidomide + Dexamethasone or DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone is more effective in treating newly diagnosed patients with multiple myeloma. The number of patients whose multiple myeloma disappears for a period of time (complete Response) will be studied to make the determination of which treatment is more effective.
Virus Vaccine
bioCSL Trivalent Influenza Virus Vaccine (CSL TIV) for Pandemic Flu
Recruiting4 awardsPhase 4
Fort Worth, Texas
This is a study to assess the safety of a bioCSL split virion, inactivated Trivalent Influenza Virus vaccine containing the 2014/2015 Northern Hemisphere strains of vaccine in children aged 5 years to less than 9 years. Comparison will be made to a licensed Quadrivalent Influenza Virus vaccine that complies with the FDA recommendations for the 2014/2015 influenza season in the US.
Pentoxifylline for Kidney Failure
Recruiting3 awardsPhase 2
Irving, Texas
Chronic kidney disease (CKD) patients have increased levels of inflammation and oxidative stress, which in turn contribute to anemia and cardiovascular disease. Pentoxifylline is known to have anti-inflammatory and anti-oxidant properties, and has shown promise in improving the treatment of patients with anemia. This study will examine the use of pentoxifylline for the treatment of anemia in chronic kidney disease.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.